Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists

Latest RA CAPITAL MANAGEMENT, L.P. Stock Portfolio

$9.44Billion– No. of Holdings #85

RA CAPITAL MANAGEMENT, L.P. Performance:
2026 Q1: -0.25%YTD: -0.25%2025: 28.52%
Performance for 2026 Q1 is -0.25%, and YTD is -0.25%, and 2025 is 28.52%.

About RA CAPITAL MANAGEMENT, L.P. and 13F Hedge Fund Stock Holdings

RA CAPITAL MANAGEMENT, L.P. is a hedge fund based in Boston, MA. On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, RA CAPITAL MANAGEMENT, L.P. reported an equity portfolio of $9.4 Billions as of 31 Mar, 2026.

The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are ASND, PCVX, RYTM. The fund has invested 24.9% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 7.1% of portfolio in VAXCYTE INC.

The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), AVIDITY BIOSCIENCES INC (RNA) and ARCELLX INC (ACLX) stocks. They significantly reduced their stock positions in CONTINEUM THERAPEUTICS INC-A and 4D MOLECULAR THERAPEUTICS IN (FDMT). RA CAPITAL MANAGEMENT, L.P. opened new stock positions in SPYGLASS PHARMA INC, ZAI LAB LTD-ADR (ZLAB) and SAREPTA THERAPEUTICS INC (SRPT). The fund showed a lot of confidence in some stocks as they added substantially to HINGE HEALTH INC-A, GENEDX HOLDINGS CORP (SMFR) and INSPIRE MEDICAL SYSTEMS INC (INSP).
RA CAPITAL MANAGEMENT, L.P. Equity Portfolio Value
Last Reported on: 15 May, 2026

RA CAPITAL MANAGEMENT, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that RA CAPITAL MANAGEMENT, L.P. made a return of -0.25% in the last quarter. In trailing 12 months, it's portfolio return was 62.63%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
spyglass pharma inc207,827,000
zai lab ltd-adr107,354,000
sarepta therapeutics inc84,920,500
damora therapeutics inc62,142,100
xencor inc59,060,700
century therapeutics inc40,125,000
mirum pharmaceuticals inc29,428,000
bioage labs inc28,869,800
New stocks bought by RA CAPITAL MANAGEMENT, L.P.

Additions

Ticker% Inc.
hinge health inc-a355
waystar holding corp266
genedx holdings corp261
inspire medical systems inc129
design therapeutics inc103
dianthus therapeutics inc62.05
solid biosciences inc60.72
wave life sciences ltd48.19
Additions to existing portfolio by RA CAPITAL MANAGEMENT, L.P.

Reductions

Ticker% Reduced
contineum therapeutics inc-a-40.54
4d molecular therapeutics in-10.67
RA CAPITAL MANAGEMENT, L.P. reduced stake in above stock

Sold off

Ticker$ Sold
invivyd inc-42,284,200
avidity biosciences inc-623,278,000
cidara therapeutics inc-743,410,000
arcellx inc-82,618,600
health catalyst inc-1,897,060
belite bio inc - adr-69,180,100
medline inc-cl a-14,070,000
orthopediatrics corp-1,952,870
RA CAPITAL MANAGEMENT, L.P. got rid off the above stocks

Sector Distribution

RA CAPITAL MANAGEMENT, L.P. has about 50.5% of it's holdings in Others sector.

  • Others
  • Healthcare
Sector%
Others50.5
Healthcare48.5
1.1

Market Cap. Distribution

RA CAPITAL MANAGEMENT, L.P. has about 1.3% of it's portfolio invested in the large-cap and mega-cap stocks.

  • UNALLOCATED
  • MID-CAP
  • SMALL-CAP
  • MICRO-CAP
  • LARGE-CAP
Category%
UNALLOCATED50.5
MID-CAP24.3
SMALL-CAP18.3
MICRO-CAP4.8
LARGE-CAP1.3

Stocks belong to which Index?

About 37% of the stocks held by RA CAPITAL MANAGEMENT, L.P. either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
Index%
Others63
RUSSELL 200037
Top 5 Winners (%)%
dianthus therapeutics inc
69.9 %
AGLE
spyre therapeutics inc
54.0 %
artiva biotherapeutics inc
50.1 %
TYRA
tyra biosciences inc
45.7 %
CCCC
c4 therapeutics inc
37.7 %
Top 5 Winners ($)$
ASND
ascendis pharma a/s - adr
159.3 M
TYRA
tyra biosciences inc
146.5 M
PCVX
vaxcyte inc
132.9 M
dianthus therapeutics inc
90.2 M
EWTX
edgewise therapeutics inc
69.7 M
Top 5 Losers (%)%
PEPG
pepgen inc
-72.8 %
WVE
wave life sciences ltd
-53.0 %
RANI
rani therapeutics holdings-a
-45.6 %
lenz therapeutics inc
-42.8 %
acrivon therapeutics inc
-42.3 %
Top 5 Losers ($)$
WVE
wave life sciences ltd
-220.2 M
RYTM
rhythm pharmaceuticals inc
-133.8 M
PEPG
pepgen inc
-95.1 M
mineralys therapeutics inc
-69.1 M
SBTX
ars pharmaceuticals inc
-39.3 M

RA CAPITAL MANAGEMENT, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL MANAGEMENT, L.P. has 85 stocks in it's portfolio. About 61.3% of the portfolio is in top 10 stocks. WVE proved to be the most loss making stock for the portfolio. ASND was the most profitable stock for RA CAPITAL MANAGEMENT, L.P. last quarter.

Last Reported on: 15 May, 2026
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions